乙肝病毒PreS1抗原和乙肝两对半结合检查的意义和应用

目的:评价检测乙肝病毒PreS1抗原与乙肝两对半相结合检查的临床应用及在健康体检中的价值。方法:将临床送检的580份血清标本用ELASE进行HBV测定,同时进行PreS1抗原检测。结果:PreS1总阳性率为33%,HBeAg阳性率为24.2%。PreS1总阳性率明显高于HBeAg阳性率。结论:PreS1抗原作为乙肝感染和复制的血清学指标敏感性与HBeAg具有一致性和相符性,对提示乙肝患者的病情发展和转归有重要临床意义。PreS1可以作为一项新的乙肝病毒复制的传染性指标。

乙肝病毒前S_1抗原与乙肝两对半检测的相关性及其临床价值

目的对乙肝两对半检测HBSAg阳性患者进行乙肝病毒前S1抗原(PreS1)检测并对比分析,进而体现乙肝病毒PreS1检测的临床价值。方法采用酶联免疫法(ELISA)对176例乙肝HBsAg阳性患者PreS1和两对半进行检测,比较各组PreS1及乙肝两对半结果,并结合临床进行分析。结果与结论血清乙肝病毒PreS1测定可以完善和补充乙肝两对半的检测,对HBV感染、复制及预后有着重要的临床意义。

乙型肝炎病毒血清标志物与PreS1抗原的关系

目的:了解PreS1与HBVM和HBV DNA的关系及其临床应用价值。方法:对306例临床血清采用ELISA方法检测HBVM和PreS1,荧光定量PCR法检测HBV DNA。结果:中HBeAg阳性146例,其中前S1阳性127例阳性率88.1%,HBeAg阴性共160例,其中前s72例阳性率45%,HBeAg阴性血清160例前s多数存在于抗HBe阳性血清中,阳性率40.6%。结论:PreS1比HBeAg更能较好反映病毒存在和复制状态.HBVM、PreS1和HBV DNA联合检测,更有利于乙肝病情监测和疗效评估。

乙肝病毒前S1抗原、乙肝病毒血清标志物和HBV-DNA联合检测的临床应用

目的探讨乙肝病毒前S1抗原(PreS1)、乙肝病毒标志物(HBVM)与乙肝病毒DNA(HBV-DNA)检测三者之间的关系,判断乙肝病毒在体内的复制情况。方法对550例乙型肝炎患者血清,用ELISA方法检测PreS1、两对半标志物,用荧光定量PCR方法定量检测HBV-DNA并分析3者之间的关系。结果HBsAg(+)、HBeAg(+)、HBcAb(+)的模式中,PreS1与HBV-DNA检出率分别为52.3%与88.4%,HBsAg(+)、HbeAb(+)、HBcAb(+)的模式中PreS1和HBV-DNA检出率分别为31.1%和47.5%,HBsAg(+)、HBcAb(+)的模式中PreS1和HBV-DNA检出率分别为47.3%和63.4%。结论PreS1能较好的反映HBV病毒感染及复制情况,可作为一种新的HBV血清标志物和监测指标,三者联合检测互相补充,更有助于临床疾病的诊治。

乙型肝炎病毒PreS1抗原与HBV血清标志物的相关性

传统乙肝血清标志物是目前我国用于乙肝检测与筛查的普及指标，但其在检测病毒复制等方面尚有不足。文章分析前Sl抗原（PreSl）和乙型肝炎病毒（HBV）血清标志物之间的关系，探讨乙型肝炎病毒前S1蛋白在临床上的应用价值。关于PreSl、抗PreSl与HBV免疫标志物的相关性。采用ELISA对306例HBsAg阳性标本进行PreSl、抗PreSl与HBV血清标志物相关性的研究证实，前S1抗原（Pre—SlAg）检测是对乙肝“两对半”，尤其是e抗原和HBV—DNA测定的重要补充和加强。

Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins

AIM: The incorporation of hepatitis B virus (HBV) preS1 region into epitope-based vaccines against HBV has been accepted widely, but the incorporate site and size of preS1 sequence is controversial. Therefore our purpose was to further investigate its immunogenic domains for the epitopebased hepatitis B vaccine design.METHODS: Eight GST fusion proteins containing overlapping preS1 fragments in preS1 (21-119) region were expressed in E.coli. Using these purified fusion proteins, the immunogenic domains in preS1 region were identified in detail in mice and humans by Western blot analysis and ELISA.RESULTS: The results in mice showed that the immunogenic domains mainly existed in preS1 (21-59) and preS1 (95-109). Similarly, these fragments had strong immunogenicity in humans; whereas the other parts except for preS1 (60-70) also had some immunogenicity.More importantly, a major immunogenic domain, preS1 (34-59), which has much stronger immunogenicity, was identified. Additionally, the antibodies against some preS1 fragments, especially preS1 (34-59), were speculated to be virus-neutralizing.CONCLUSION: Eight GST fusion proteins containing overlapping preS1 fragments were prepared successfully. They were used for the study on the immunogenic domains in preS1 (21-119) region. The preS1 (34-59) fragments were the major immunogenic domains in the preS1 region, and the antibodies against these fragments were speculated to be virus-neutralizing. Therefore, the incorporation of preS1 (34-59) fragments into epitopebased HBV vaccines may be efficient for enhancement of immune response. Additionally, the results also imply that there are more complex immune responses to preS1 region and more abundant immunogenic domains in humans.

THE COEXPRESSION OF THE preS1(1-42) AND THE CORE(1-144)ANTIGEN OF HBV IN E.coli

Objective.To study the therapeutic T cell vaccine for the treatment of chronic hepatitis B by improving the cellular immunization of HBsAg vaccine with the coexpression of the preS1(1-42)and the Core(1-144)anti-gen of HBV in E.coli.Methods.The genes of HBcAg (1-144)and preS1(1-42)were amplified and fused by PCR.This fused gene was inserted in the prokaryotic expression vector pET-11d and expre ssed in E.coli.Results.It was showed by SDS-PAGE that the pr otein molecular weight of the coexpr ession product was about 20kD,20%of all bacteria prote in.The monoclonal antibodies again st core and preS1antibody could re-act with this fused protein by Western-blot technique respectively.The fused gene was verified by sequencin g.Under the immune electron microscop y,this fused protein is typical particles of HBcAg but in an aggregated form.Conclusion.The results might aid for studying T c ell immunotherapeutic vaccine for c hronic hepatitis B.

前S1蛋白(PreS1)在乙型肝炎诊断中的作用

目的探讨HBV感染者血清中PreS1与HBV-DNA、HBeAg三者间的关系,进而评估PreS1在HBV感染、复制、诊断中的作用。方法收集1750例乙型肝炎患者血清,按不同HBV-M进行分组:HBsAg(+)、HBeAg(+)、HBcAb(+)为A组,HBsAg(+)、HBeAb(+)、HBcAb(+)为B组,HBsAg(+)、HBcAb(+)为C组,HBsAg(+)为D组,采用酶联免疫法(ELISA)检测乙肝病毒PreS1与HBV血清标志物,荧光定量PCR法检测HBV-DNA。结果以HBV-DNA>5×102拷贝/mL为阳性诊断标准,不同HBV-M模式中,PreS1与HBV-DNA的检出率无显著差异(P>0.01),PreS1与HBV-DNA的总符合率高于HBeAg与HBV-DNA的符合率,在HBeAg(-)患者中仍可不同程度地检出PreS1与HBV-DNA。结论PreS1可作为HBV感染、复制的一项新指标,在乙型肝炎诊断中具有很大的应用价值。

乙肝HBV DNA荧光定量检测与乙肝五项及perS1的相关性分析

目的分析乙肝五项及PreS1-Ag联合检测与HBV-DNA结果的一致性,探讨三者的相关性。方法分别采用ELISA、PCR的方法对328例乙肝患者进行HBV五项、前S1抗原及HBV-DNA的检测。结果在HBsAg(+)HBeAg(+)HBcAb(+)的模式下,HBV-DNA、PreS1-Ag的阳性率分别为81.0%、79.4%,在HBsAg(+)HBeAg(+)的模式下,HBV-DNA、PreS1-Ag的阳性率分别为85.7%、80.0%,两者的检出率差异无统计学意义(P>0.05);在HBsAg(+)HBeAb(+)HBcAb(+)模式下,HBV-DNA、PreS1-Ag的阳性率分别为40.8%、35.7%,在HBsAg(+)HBcAb(+)模式下,HBV-DNA、PreS1-Ag的阳性率分别为54.5%、48.5%,在HBsAg(+)HBeAb(+)模式下,HBV-DNA、PreS1-Ag的阳性率分别为50.0%、50.0%,在HBsAg(+)模式下,HBV-DNA、PreS1-Ag的阳性率分别为100%、100%。PreS1-Ag和HBeAg的阳性检出率在HBV-DNA阳性与阴性标本中差异均有统计学意义(P<0.005)。结论 PreS1-Ag、乙肝五项及HBV-DNA的结果密切关联,联合检测PreS1-Ag、乙肝五项能够很好的反映乙肝病毒的复制及传染性,对于乙肝的诊治具有指导意义。